|
 |
|
Program - Sunday 9 November 2008 |
| |
|
8:00-12:00 |
Pre-Congress Short Courses |
|
|
12:00-13:00 |
Exhibits & Poster Presentations Viewing – Session I |
|
|
|
13:00-13:10 |
WELCOME FROM THE ISPOR PRESIDENT |
|
Chris L. Pashos, PhD, 2008-2009 ISPOR President & Vice President, HERQuLES, Abt BioPharma Solutions, Inc. Lexington, MA, USA |
13:10-13:20 |
WELCOME TO GREECE |
|
John Yfantopoulos PhD and the Greek Advisory Committee |
13:20-13:30 |
CONGRESS INTRODUCTION AND OBJECTIVES |
|
Uwe Siebert MD, MPH, MSc, ScD, and John Yfantopoulos PhD, Program Planning Committee Co-Chairs |
|
13:30-14:45 |
First Plenary Session |
|
Health Technology Assessment (HTA) in Europe – Is Harmonization Possible?
Health technology assessment (HTA) is a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust manner. Its aim is to inform the formulation of safe, effective, health policies that are patient focused and seek to achieve best value [ref: EUnetHTA]. European countries have established independent evaluation processes for health technologies. Whereas a health technology’s clinical outcomes are less country-specific, economic, ethical and legal aspects of a technology are more country-specific. Although initiatives to harmonize European evaluation processes are underway such as the EUnetHTA, individual countries still have different HTA requirements. This plenary session will focus on the diversity in HTA processes, and their use in decision-making, as well as efforts to harmonize these HTA processes in Europe.
 |
Moderator:
Uwe Siebert MD, MPH, MSc, ScD,
Professor/Chair, Department of Public Health, Medical Decision Making and Health Technology Assessment at the University of Health Sciences, Medical Informatics and Technology, i.T, Austria |
| Speakers: |
|
 |
Peter Sawicki MD, PhD
Director, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany; |
 |
Louise Longworth PhD
Senior Research Fellow, School of Health & Related Research (ScHARR), University of Sheffield, Sheffield, UK; |
 |
Finn Boerlum Kristensen MD, PhD
Director & Professor, Danish Centre for Health Technology Assessment, National Board of Health, Copenhagen, Denmark; Adjunct Professor, University of Southern Denmark; Project Leader, European Network for HTA (EUnetHTA) |
|
|
14:45-15:15 |
Break, Exhibits & Poster Presentations Viewing – Session I |
|
|
15:15-16:15 |
Podium Presentations - Session I |
| |
| Economic Evaluations I |
| EE1 |
DISCRETE CHOICE EXPERIMENTS OF COMPLEX HEALTH CARE DECISIONS: DOES HIERARCHICAL INFORMATION INTEGRATION OFFER A SOLUTION? |
|
Van Helvoort-Postulart D1, Dellaert B2, Van der Weijden T3, Von Meyenfeldt M1, Dirksen CD1 |
|
1Maastricht University Medical Center, Maastricht, The Netherlands, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3Maastricht University, Maastricht, The Netherlands |
| EE2 |
STANDARDIZED TYPE 2 DIABETES COMPLICATION COSTS FROM US COMMERCIAL PAYERS TO BE USED IN MODELING THE LONG-TERM ECONOMIC OUTCOMES OF DIABETES COMPLICATIONS |
|
Minshall ME1, Pelletier EM2, Smith PJ3, Forma FM4 |
|
1IMS Health, Noblesville, IN, USA, 2IMS Health Consulting, Watertown, MA, USA, 3PharMetrics, a unit of IMS, Watertown, MA, USA, 4Novo Nordisk Inc, Princeton, NJ, USA |
| EE3 |
VARIATION IN DIRECT MEDICAL COSTS BY DISEASE SEVERITY AMONG PERSONS WITH CHRONIC HEPATITIS C VIRUS |
|
Davis KL1, Mitra D1, Medjedovic J2, Beam C3, Rustgi V4 |
|
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland, 3Human Genome Sciences, Inc, Rockville, MD, USA, 4Georgetown University Medical Center, Fairfax, VA, USA |
| EE4 |
CAREER INTERRUPTIONS AND SICK LEAVES AMONG FIBROMYALGIA PATIENTS |
|
Le Lay K1, Boussetta S1, Moldofsky H2, Taieb C1 |
|
1Pierre Fabre, Boulogne, France, 2Centre for Sleep and Chronobiology, Toronto, ON, Canada |
| |
| Performance of HTA Agencies |
| HT1 |
A SYSTEMATIC FRAMEWORK FOR COMPARING METHODS, PROCEDURES, AND IMPACT ACROSS HTA AGENCIES |
|
Schwarzer R, Siebert U |
|
UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T, Tirol, Austria |
| HT2 |
UPDATE OF RESULTS AND OUTCOMES OF NICE SINGLE TECHNOLOGY APPRAISALS - ECONOMIC CRITICISMS |
|
Karia R, Plested M, Cann K, Zwaferink H |
|
Heron Evidence Development Ltd, Letchworth Garden City, UK |
| HT3 |
A COMPARISON OF REASONS FOR RECOMMENDATION AND REJECTION IN FOUR HEALTH TECHNOLOGY APPRAISAL SYSTEMS: NICE, SMC, CADTH AND PBAC |
|
Cann K, Karia R, Plested M, Samuels E |
|
Heron Evidence Development Ltd, Letchworth Garden City, UK |
| HT4 |
HEALTH TECHNOLOGY ASSESSMENTS: ARE THEY RELEVANT TO CLINICAL PRACTICE? |
|
Zhang B1, Van Staa TP2 |
|
1General Practice Research Database, London, Middlesex, UK, 2General Practice Research Database, London, UK |
| |
| Medical Device Economic Evaluations |
| MD1 |
HEALTH ECONOMIC ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED TO MULTIPLE DAILY INJECTIONS FOR THE TREATMENT OF TYPE 1 DIABETES IN POLAND |
|
Clegg JP1, Wéry E1, Karamalis M2, Pokorski J2, Mlynarski W3, Valentine WJ1, Goodall G4 |
|
1IMS Health, Allschwil, Switzerland, 2Medtronic Poland Sp. z o.o, Warsaw, Poland, 3Medical University of Lodz, Lodz, Poland, 4IMS Health, Basel, Switzerland |
| MD2 |
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF ENDEVOR® DRUG-ELUTING STENT COMPARED TO BARE-METAL STENTS AND CORONARY ARTERY BYPASS GRAFT SURGERY IN SPAIN |
|
Rodriguez Barrios JM1, Moreu J2, Cequier A3, Brosa M4, Vazquez N5, Hernandez J6, Crespo C7, Brasseur P8 |
|
1Medtronic Iberia, Madrid, Madrid, Spain, 2Virgen de la Salud Hospital, Toledo, Toledo, Spain, 3Belvitge Hospital, Barcelona, Barcelona, Spain, 4Oblikue, Barcelona, Barcelona, Spain, 5Juan Canalejo Hospital, A Coruna, A Coruna, Spain, 6Malaga Clinic Hospital, Malaga, Malaga, Spain, 7Oblikue Consulting, Barcelona, Spain, 8Medtronic Sarl, Tolochenaz, Switzerland |
| MD3 |
COST-EFFECTIVENESS OF LUMBAR DISC ARTHROPLASTY VERSUS LUMBAR FUSION FROM A HEALTH CARE SYSTEM'S PERSPECTIVE IN AUSTRIA |
|
Tuschel A, Meissl M, Ogon M |
|
Orthopaedic Hospital Vienna Speising, Vienna, Austria |
| MD4 |
UNCOVERING ATRIAL FIBRILLATION (AF) IN PATIENTS WITH STROKE OF UNDETERMINED AETIOLOGY: COST-EFFECTIVENESS OF ADDING IMPLANTABLE CARDIAC MONITORS (ICMS) TO THE DIAGNOSTIC PATHWAY |
|
Murthy A1,
Tsintzos S2 |
|
1Medtronic International, Tolochenaz, Vaud, Switzerland, 2Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland |
| |
| Mental Health I (Attention-Deficit/Hyperactivity Disorder in Europe) |
| MH1 |
HOW MUCH SHOULD WE BE PREPARED TO PAY FOR PSYCHOSOCIAL INTERVENTIONS FOR PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)? |
|
Schlander M1, Schwarz O1, Hakkaart-van Roijen L2, Jensen PS3, Persson U4, Santosh PJ5, Trott GE6, MTA Cooperative Group _7 |
|
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Erasmus MC, Rotterdam, The Netherlands, 3Columbia University, New York, NY, USA, 4The Swedish Institute for Health Economics, IHE, Lund, Sweden, 5Institute of Child Health - Great Ormond Street Hospital, London, UK, 6University of Wuerzburg, Aschaffenburg, Germany, 7National Institute of Mental Health, Bethesda, MD, USA |
| MH2 |
THE SUSTAINED DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER FROM CHILDHOOD TO ADULTHOOD: A MEDICAID STUDY |
|
Chen H, Sudharshan L |
|
University of Houston, Houston, TX, USA |
| MH3 |
COST-EFFECTIVENESS OF LONG-ACTING METHYLPHENIDATE FOR TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS IN FINLAND: AN EVALUATION BASED UPON A RANDOMIZED CLINICAL TRIAL (RCT) |
|
Schlander M1, Hjelmgren J2 |
|
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2Janssen-Cilag AB, Sollentuna, Sweden |
| MH4 |
HEALTH SERVICE EXPENDITURES FOR CHILDREN AND ADOLESCENTS WITH AND WITHOUT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY – IMPACT OF COEXISTING CONDITIONS |
|
Schlander M1, Schwarz O1, Trott GE2, Viapiano M3, Bonauer N3 |
|
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2University of Wuerzburg, Aschaffenburg, Germany, 3Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany |
| |
| Quality of Life/Preference-Based Measures I |
| QL1 |
AGGREGATION OF DATA FROM MULTIPLE LANGUAGES AND CULTURES: REPORT FROM THE ISPOR TASK FORCE ON TRANSLATION AND LINGUISTIC VALIDATION |
|
Wild D1, Martin M2, Hareendran A3, von Maltzahn R1 |
|
1Oxford Outcomes Ltd, Oxford, UK, 2Health Research Associates Inc, Seattle, WA, USA, 3Pfizer, Ltd, Sandwich, UK |
| QL2 |
TRANSLATION OF THE COLUMBIA SUICIDE SEVERITY RATING SCALE (C-SSRS) FOR USE IN 33 COUNTRIES |
|
Fernandez N1, Grataloup G1, Posner K2 |
|
1Mapi Research Institute, Lyon, France, 2New York State Psychiatric Institute, New York, NY, USA |
| QL3 |
ACCESS TO HEALTH-RELATED QUALITY OF LIFE (HRQL) INSTRUMENTS AND THEIR TRANSLATIONS IN THE LIGHT OF EMEA RECOMMENDATIONS |
|
Anfray C, Emery MP |
|
Mapi Research Trust, Lyon, France |
| QL4 |
PREDICTING EQ-5D, SF-6D AND 15D UTILITIES FROM EORTC QLQ-C30 DATA |
|
Kontodimopoulos N1, Paliouras D2, Pappa E1, Papadopoulos AA3, Aletras VH4, Niakas D1 |
|
1Hellenic Open University, Patras, Greece, 2Theagenio Cancer Hospital, Thessalonica, Greece, 3Attikon University Hospital, Athens, Greece, 4University of Macedonia, Thessalonica, Greece |
|
|
16:15-16:30 |
Break, Exhibits & Poster Presentations Viewing – Session I |
|
|
16:30-17:30 |
Podium Presentations – Session II |
|
| Cardiovascular Disease Evaluations |
| CV1 |
WHAT IS THE CLINICAL BENEFIT OF PREVENTING NON-FATAL MYOCARDIAL INFARCTIONS? |
|
Eisenstein EL1, Cowper PA1, Bae JP2, Kong DF1, Ramaswamy K3, Anstrom KJ1 |
|
1Duke Clinical Research Institute, Durham, NC, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Daiichi Sankyo Inc, Parsippany, NJ, USA |
| CV2 |
A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH ATRIAL FIBRILLATION: AF-QOL |
|
Arribas F1, Ormaetxe JM2, Peinado R3, Fernandez C4, Ramírez P4, Badia XB5, Lara N5 |
|
1Hospital 12 de Octubre, Madrid, Spain, 2Hospital de Basurto, Bilbao, Spain, 3Hospital La Paz, Madrid, Spain, 4MEDA Pharma, Madrid, Spain, 5IMS Health, Barcelona, Spain |
| CV3 |
PREDICTED OPTIMAL LIPID VALUE ATTAINMENT WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN PATIENTS WITH MULTIPLE LIPID ABNORMALITIES |
|
Sorensen SV1, Webb SF2, Burge RT2 |
|
1United BioSource Corporation, Bethesda, MD, USA, 2Abbott Laboratories, Abbott Park, IL, USA |
| CV4 |
COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN STABLE ANGINA PATIENTS IN THE THE NETHERLANDS |
|
Nuijten MJ1, Redekop WK2 |
|
1Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam, The Netherlands |
| |
| Economic Evaluations II |
| PRS8 |
TOTAL COSTS OF TOBACCO FOR SOCIETY – WHAT ARE THE RETURNS ON INVESTMENTS FOR DIFFERENT GOVERNMENTAL INTERVENTIONS? |
| |
Reissell E1, Herse F1, Väänänen JJP1, Linden K2, Kotomäki T2, Parvinen PMT1 |
| |
1Nordic Healthcare Group, Helsinki, Finland, 2Pfizer Oy, Helsinki, Finland |
| |
|
| EE6 |
COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK |
|
Ray JA1, Carr E1, Geary U2 |
|
1F. Hoffmann - La Roche, Basel, Switzerland, 2Roche Products Limited, Hertfordshire, UK |
| EE7 |
ECONOMIC ANALYSIS OF PROPHYLACTIC CERVICAL CANCER VACCINATION IN ITALY: THE NATIONAL AND REGIONAL LEVEL |
|
Cavallo M1, Cipriani F2, Demarteau N3, Gerzeli S1, Marocco A2, Bamfi F2 |
|
1Bocconi University, Milano, Italy, 2GlaxoSmithKline Spa, Verona, Italy, 3GlaxoSmithKline Biologicals, Wavre, Belgium |
| EE8 |
COST EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH OXALIPLATIN (XELOX) COMPARED TO FOLFOX (5-FU, LV, OXALIPLATIN) FOR THE TREATMENT OF METASTATIC CARCINOMA OF THE COLON OR RECTUM (CRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE |
|
Millar DR1, Ducournau P2, McDonald A3 |
|
1Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK, 2F. Hoffmann-La Roche, Basel, Switzerland, 3Western Infirmary, Glasgow, UK |
| |
| Mental Health II (Schizophrenia in Europe) |
| MH5 |
EFFECT OF A NURSE TELEPHONE FOLLOW-UP ON THERAPEUTIC ADHERENCE OF PATIENTS WITH SCHIZOPHRENIA |
|
Maurino J1, Montes JM2, Saiz Ruiz J3, Claret J4, Diez T1 |
|
1AstraZeneca, Madrid, Spain, 2Hospital del Sureste, Arganda del Rey, Spain, 3Hospital Ramon y Cajal, Madrid, Spain, 4Fundació Hospital de Día Nou Barris, Barcelona, Spain |
| MH6 |
ADHERENCE, PERSISTENCE, COSTS AND QUALITY OF LIFE IN PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS: RESULTS FROM THE COMETA STUDY |
|
Mantovani LG1, Ferrannini L2, Mencacci C3, Pirfo E4, Bernareggi M5, Giustra MG5, Berto P6, Sturkenboom MC7, Scalone L8 |
|
1University of Naples, Federico II, Naples, Italy, 2Mental Health Department ASL 3, Genova, Italy, 3Mental Health Department, Milan, NA, Italy, 4Mental Health Department G. Maccacaro, Torino, NA, Italy, 5Janssen-Cilag SpA, Cologno Monzese, Milan, NA, Italy, 6PBE consulting, Verona, Italy, 7Erasmus University Medical Center, Soest, The Netherlands, 8Centre of Pharmacoeconomics, Milan, Italy |
| MH7 |
PATIENT REPORTED OBJECTIVES AND PRIORITIES FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY: A MIXED METHODS APPROACH TO CAPTURING THE PATIENT'S PERSPECTIVE |
|
Kinter ET1, Rudolph I2, Schmeding A2, Bridges JF1 |
|
1Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, 2Janssen-Cilag GmbH, Neuss, Germany |
| MH8 |
DIRECT COST OF TREATING PATIENTS WITH SCHIZOPHRENIA IN GREECE: REAL-WORLD DATA FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) |
|
Geitona M1, Kousoulakou C2, Ollandezos M3, Papanicolaou S4, Athanasakis K3, Tsiantou V3, Kyriopoulos J3 |
|
1University of Thessaly, Volos, Greece, 2Foundation for Economic and Industrial Research, Athens, Greece, 3National School of Public Health, Athens, Greece, 4Janssen-Cilag Pharmaceutical SACI, Athens, Attika, Greece |
| |
| Modelling in Economic Evaluation |
| MO1 |
ADVANTAGES AND DISADVANTAGES OF MARKOV MODELS VERSUS DISCRETE EVENT MODELS FOR SIMULATING PATIENT FLOWS |
|
Al MJ1, Welte R2 |
|
1Erasmus MC, Rotterdam, The Netherlands, 2GlaxoSmithKline, Munich, Germany |
| MO2 |
INCORPORATING CALIBRATED MODEL PARAMETERS INTO SENSITIVITY ANALYSES: DETERMINISTIC AND PROBABILISTIC APPROACHES |
|
Taylor DC1, Kruzikas D2, Pawar V3, Gilmore K1, Naik S1, Weinstein MC4 |
|
1i3 Innovus, Medford, MA, USA, 2GlaxoSmithKline, Philadelphia, PA, USA, 3Innovus Research, Inc, Medford, MA, USA, 4i3 Innovus Research Inc., Harvard School of Public Health, Harvard Medical School, Boston, MA, USA |
| MO3 |
COMPARING METHODS OF DATA SYNTHESIS: UPDATING PARAMETERS OF AN EXISTING PROBABILISTIC COST-EFFECTIVENESS MODEL |
|
Oppe M, Al MJ, Rutten-van Mölken MP |
|
Erasmus MC, Rotterdam, The Netherlands |
| MO4 |
TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS: THE CASE OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE THE NETHERLANDS |
|
Joore MA1, Tjan Heijnen V1, Severens JL1, Novák A2, Oron U3, Pompen M3, Essers BA1 |
|
1University Hospital Maastricht, Maastricht, The Netherlands, 2Anovák-Services, Apeldoorn, The Netherlands, 3Roche Netherland BV, Woerden, The Netherlands |
| |
| Quality of Life/Preference-Based Measures II |
| QL5 |
COMPARISON OF EQ-5D AND HUI3 IN PATIENTS WITH TINNITUS |
|
Maes IH1, Joore MA1, Cima RF2, Vlaeyen JW2, Anteunis LJ1 |
|
1University Hospital Maastricht, Maastricht, The Netherlands, 2Maastricht University, Maastricht, The Netherlands |
| QL6 |
ROLE OF DISEASE SPECIFIC INSTRUMENTS IN THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CANCER CLINICAL TRIALS |
|
Narvilkar P, Mahajan A, Dimri S, Kumar R, Sehgal M |
|
Heron Health Private Ltd, Chandigarh, India |
| QL7 |
INTERPRETING SCORES ON THREE COPD PATIENT-REPORTED OUTCOME MEASURES |
|
McKenna SP1, Twiss J1, Meads DM1, Revicki D2, Pokrzywinski R3, Gale R4 |
|
1Galen Research, Manchester, UK, 2United BioSource Corporation, Bethesda, MD, USA, 3United Biosource Corporation, Pittsburgh, PA, USA, 4Novartis AG, Horsham, UK |
| QL8 |
COMPARISON OF CANCER-RELATED FATIGUE USING A ONE- VERSUS FOUR-WEEK RECALL PERIOD |
|
Lai JS1, Cook K2, Stone A3, Beaumont J4, Cella D4 |
|
1Evanston Northwestern Healthcare/Northwestern University, Evanston, IL, USA, 2University of Washington, Houston, TX, USA, 3Stony Brook University, Stony Brook, NY, USA, 4Evanston Northwestern Healthcare, Evanston, IL, USA |
|
17:30-18:30 |
Poster Author Discussion Hour – Session I |
|
|
|
17:30-19:30 |
Exhibitors’ Open House Reception |
|
|
17:45-19:15 |
ISPOR Eastern European Chapters Forum |
|
Real World Data for Pharmacoeconomic Evaluation in Central and Eastern European Countries & Croatian Current Issue in Vaccination - Epidemiological and Pharmacoeconomical Approach
(Slovakia, Hungary, Czech Republic and Croatia)
The forum will focus on optimal use of real world data and transferability of economic evaluations, including methods, clinical and economic results. The
session is intended to facilitate the international collaboration among professionals in countries with similar backgrounds and geographic locations. In addition,
ISPOR-Croatia will address the vaccination issues currently facing their country.
Moderators: Zoltán Kaló MD, BE, MSc, PhD, Associate Professor & Programme Director, Health Economics Research Centre, Eötvös Loránd University, Budapest,
Hungary; Tomáš Doležal MD, PhD, MuDr, Professor, Department of Pharmacology, 3rd Medical Faculty, Charles University, Prague,Czech Republic
Speakers: Ljubica Besker-Ivasovic MD, PhD, Executive Master Sanitary Economy and Management, Capoclinica, Clinica S. Anna, Bellinzona, Switzerland;
Tomas Tesar PharmD, PhD, MBA, Faculty of Pharmacy, Comenius University Bratislava, Slovakia; Tomasz Hermanowski PhD, Professor of Warsaw Technical
University Business School, Warsaw, Poland; Zoltán Kaló MD, BE, MSc, PhD, Associate Professor & Programme Director, Health Economics Research Centre,
Eötvös Loránd University, Budapest, Hungary; Tomáš Doležal MD, PhD, MuDr, Professor, Department of Pharmacology, 3rd Medical Faculty, Charles University,
Prague,Czech Republic
|
| |
11th Annual European Congress Main Page
|
|
